VolitionRx Ltd (VNRX) income statement
VNRXNYSEIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.18−0.01 (-3.02%)
Close on Nov 18, 2026Market cap $2.50MP/E –Yield –
VolitionRx Ltd income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -790.2%
- Net margin
- -1043.1%
- Return on equity, FY2025
- 79.0%
Financial strength
- Current ratio
- 0.30
- Debt to equity
- -0.22
- Debt to assets
- 85.0%
- Cash to current liabilities
- 20.8%
Valuation
- P/E ratio
- –
- Price to sales
- 1.02
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?